Navigation Links
Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
Date:9/11/2012

HAMILTON, N.J., Sept. 11, 2012 /PRNewswire/ -- Medical Diagnostic Laboratories, L.L.C. (MDL), a CLIA-certified infectious disease laboratory which specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses, announced that it is now offering an azithromycin resistance reflex assay for Chlamydia trachomatis. MDL is believed to be the first and only clinical laboratory to offer the antibiotic resistance for this sexually transmitted pathogen. Drug resistance testing has become an essential tool to assist clinicians in the selection of appropriate drug regimens for effective treatment. The azithromycin resistance reflex assay for Chlamydia trachomatis will be performed at no additional charge when Chlamydia trachomatis is detected in a patient's specimen.

Chlamydia is the most frequently reported sexually transmitted disease in the United States and is caused by the bacterium Chlamydia trachomatis. In 2010, over 1.3 million chlamydial infections were reported to the Centers for Disease Control and Prevention (CDC) from 50 states and the District of Columbia. Asymptomatic infection is very common in both men and women and can therefore "silently" cause irreversible damage before symptoms are experienced or a proper diagnosis is made. Left untreated, a chlamydial infection can spread to a woman's uterus and fallopian tubes, and cause pelvic inflammatory disease (PID), ectopic pregnancy, and infertility.

To prevent the spread of the chlamydial infection and cure the patient, an effective treatment must be initiated as quickly as possible. Although most genital infections caused by Chlamydia trachomatis are effectively treated with azithromycin, recent studies indicate that a subset of strains are resistant to this antibiotic. This detection of resistance of Chlamydia trachomatis to azithromycin is therefore important when choosing proper antibiotic therapy. MDL has developed a molecular diagnostic sequencing assay that can detect these specific azithromycin-resistant Chlamydia trachomatis strains. This test is now being performed at no additional charge for any positive Chlamydia trachomatis specimens that have been detected by MDL's real-time PCR diagnostic assay.

Dr. Eli Mordechai, Chief Executive Officer (CEO), in announcing the new assay, stated: "We are pleased to add reflexive testing for azithromycin resistance to our Chlamydia trachomatis assay. The molecular-based testing that we have developed can discriminate between antibiotic susceptible and resistant infections. This information allows a physician, at the time of diagnosis, to provide the most rapid and cost-effective treatment to their patients. Recognizing the importance of the increasing antibiotic resistance among human pathogens, MDL is the only laboratory to now offer molecular diagnostic antibiotic resistance testing at no additional charge for three of the most common sexually transmitted diseases: Neisseria gonorrhoeae, Trichomonas vaginalis, and now for the first time, Chlamydia trachomatis."

MDL is a member of the Genesis Biotechnology Group located in Hamilton, New Jersey in "Einstein's Alley," the research and technology corridor of New Jersey, in close proximity to major metropolitan centers in New York, New Jersey and Pennsylvania.

To find out more about this test and other MDL testing, please visit www.mdlab.com.

Contact: Martin Adelson, Ph.D.
madelson@mdlab.com
609.570.1015
www.mdlab.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Medical Diagnostic Laboratories, L.L.C.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Medical Marijuana, Inc. Portfolio Company PhytoSPHERE Systems Announces Successful Production of Hemp Harvesting for High Value CBD Oil
2. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
3. Tufts Medical Center Announces Inaugural INNOVATION Day: Innovating a Path to Market
4. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
5. Global Medical Laboratories Industry
6. MarketsandMarkets: Global Refurbished Medical Equipments Market worth $8.45 Billion by 2017
7. Medical Marijuana Inc. Product, CanChew Bio-Technologies
8. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
9. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
10. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Prepare for FDA Inspections of Their Quality Systems
11. Department of Defense Exercises Options Under Contract for Nerve Agent Medical Countermeasure Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... DUBLIN , June 22, 2016 Research ... and Global Markets" report to their offering. ... $39.4 billion in 2014 from $29.3 billion in 2013. The market ... (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion ... and projected product forecasts during the forecast period (2015 to 2020) ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):